title: Cost analysis of erythropoietic-stimulating therapy dosing in oncology inpatients.
abstract: BACKGROUND
  Inpatient costs associated with different erythropoietic-stimulating therapy regimens have not been compared in an oncology setting.
  
  
  OBJECTIVE
  To conduct a cost analysis of different regimens of epoetin alfa (EPO) and darbepoetin alfa (DARB) in an inpatient oncology setting.
  
  
  METHODS
  A retrospective evaluation of oncology diagnosis-related group discharges during 2003, in 30 community hospitals, identified EPO treatment patterns. Wholesale acquisition costs were determined for patients who received EPO 40,000 units or more once weekly. Potential differences in costs were calculated using conversion ratios for an equivalent EPO dose 3 times weekly or DARB dose once weekly (EPO:DARB ratio 260:1, approximating DARB 150 microg once weekly). A sensitivity analysis was performed using an EPO:DARB ratio of 400:1, approximating DARB 100 microg once weekly (1.5 microg/kg).
  
  
  RESULTS
  Among the 1410 EPO doses administered (n = 677 pts.), a dose of 40,000 units or more was used 44% of the time (n = 311 pts.), with dosing initiated on average 5.6 days after admission. For these 311 evaluable patients, switching from EPO 40,000 units once weekly to EPO 10,000 units 3 times weekly reduced per-patient and total drug acquisition costs by approximately 50% (704 US dollars vs 359 US dollars and 218,938 US dollars vs 111,615 US dollars, respectively). Relative to EPO once weekly, switching patients to DARB resulted in increased drug acquisition costs at the 260:1 conversion and lower costs at the 400:1 conversion. However, EPO 3 times weekly remained the least costly option by 44-63%. The cost-savings realized with EPO 10,000 units 3 times weekly increased with longer duration of hospitalization.
  
  
  CONCLUSIONS
  In an inpatient setting, use of EPO 10,000 units 3 times weekly may minimize expenditures associated with treatment of cancer-related anemia using erythropoietic-stimulating therapies.
authors.affiliation: Cardinal Health Clinical Research Group, Dallas, TX 75204, USA. killian@Cardinal.com
authors.forename: Aaron D
authors.initials: AD
authors.lastname: Killian
authors.forename: Vikas
authors.initials: V
authors.lastname: Gupta
authors.forename: Alisa E
authors.initials: AE
authors.lastname: Goetz
mesh_terms: D000465:Algorithms; D003365:Costs and Cost Analysis; D000068256:Darbepoetin alfa; D004305:Dose-Response Relationship, Drug; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics* / Q000627:therapeutic use*; D006397:Hematinics / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000191:economics*; D009503:Neutropenia / Q000188:drug therapy* / Q000191:economics*; D011994:Recombinant Proteins
chemical_list: D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa